Hypothesis

Core idea: Elastin fragments generated by MMPs act as damage‑associated molecular patterns (DAMPs) that bind Toll‑like receptors (TLR2/4) on vascular smooth muscle cells (VSMCs), triggering a NADPH oxidase‑dependent ROS burst. This ROS surge inhibits autophagy through mTORC1 activation and simultaneously promotes YAP/TAZ nuclear translocation, synergizing to push VSMCs toward an osteogenic phenotype.

Mechanistic reasoning

• Elastin fragmentation → DAMP signaling: Degraded elastin releases bioactive peptides that bind the elastin‑laminar receptor (ELR) and also engage TLR2/4, as shown for other matrix DAMPs[https://www.ahajournals.org/doi/10.1161/atvbaha.119.313129]. TLR activation recruits MyD88 and triggers NADPH oxidase (NOX2/4) assembly, raising intracellular ROS.

• ROS → autophagy suppression: Elevated ROS activates mTORC1 via oxidation of TSC2 and promotes p62 accumulation, blocking autophagosome formation[https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2025.1636812/full]. Defective autophagy in VSMCs is already linked to Ca²⁺‑driven osteogenesis, creating a feed‑forward loop.

• ROS → YAP/TAZ activation: ROS inhibits Hippo kinases LATS1/2, allowing YAP/TAZ to accumulate in the nucleus[https://pmc.ncbi.nlm.nih.gov/articles/PMC11306354/]. Nuclear YAP/TAZ drives transcription of CTGF and Cyr61, which further enhance BMP‑2/SMAD signaling and osteogenic gene expression (RUNX2, SP7).

• Integration with known pathways: The ROS‑autophagy‑YAP/TAZ axis converges on the same downstream effectors highlighted in the literature: elastin‑derived peptide‑ELR binding, BMP‑2‑SMAD5 signaling, and MGP deficiency. Thus, elastin fragments act as an upstream initiator that amplifies multiple active stiffening pathways simultaneously.

Testable predictions

1. In vitro: Treating human aortic VSMCs with elastin‑derived peptides (e.g., VGVAPG) will increase TLR2/4 phosphorylation, ROS production (measured by DCFDA), p‑mTORC1 levels, and nuclear YAP/TAZ, while decreasing LC3‑II/I ratio. Blocking TLR2/4 with specific antibodies or using NOX inhibitors (GSK‑2795039) will rescue autophagy and prevent osteogenic conversion (ALP activity, Alizarin Red staining).
2. Ex vivo: Mouse aortae from aged wild‑type mice exposed to elastin peptides will show elevated VSMC TLR2/4 signaling and calcification; this will be attenuated in VSMC‑specific Tlr2/Tlr4 double knockouts or in mice treated with the autophagy inducer spermidine.
3. In vivo: Administration of a TLR2/4 antagonist (e.g., TAK‑242) combined with a YAP/TAZ inhibitor (verteporfin) to aged ApoE⁻/⁻ mice will reduce elastin calcification (von Kossa staining) and improve pulse wave velocity more effectively than either agent alone, supporting a synergistic upstream‑downstream model.
4. Human relevance: Plasma levels of specific elastin‑derived peptides will correlate positively with circulating TLR2/4 agonists (HMGB1, S100A8/9) and inversely with autophagic flux markers (LC3‑II in circulating monocytes) across a cohort of young to elderly subjects.

Falsifiability

If elastin fragments fail to activate TLR2/4‑ROS signaling, or if TLR/NOX blockade does not restore autophagy or prevent VSMC osteogenesis despite robust elastin degradation, the hypothesis would be refuted. Similarly, if YAP/TAZ remains cytosolic despite ROS elevation in VSMCs treated with elastin peptides, the proposed ROS‑YAP/TAZ link would be invalid.

Implications

Targeting the elastin‑fragment/TLR/ROS axis could break the cycle of active stiffening, offering a combinatorial strategy that addresses degradation‑driven signaling, autophagy loss, and mechanotransduction simultaneously—aligning with the field’s shift toward multi‑target repair approaches.